Components of the metabolic syndrome and risk of type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 8, 2016, Pages 3212-3221

  Marott, Sarah C W ^a,c   Nordestgaard, Børge G ^a,c   Tybjærg Hansen, Anne ^a,b,c   Benn, Marianne ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; GENETIC VARIATION; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; COMPLICATION; DENMARK; DIABETES MELLITUS, TYPE 2; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84984669452     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3777     Document Type: Article

References (43)

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;(120):1640-1645.
2. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;(31):1898-1904.
3. Salminen M, Kuoppamaki M, Vahlberg T, Raiha I, Irjala K, Kivela SL. Metabolic syndrome defined by modified International Diabetes Federation criteria and type 2 diabetes mellitus risk: a 9-year follow-up among the aged in Finland. Diab Vasc Dis Res. 2013;(10): 11-16.
4. Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;(371):1927-1935.
5. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;(27):1133-1163.
6. ThomsenM,Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med. 2014;(174):15-22.
7. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva, Switzerland: World Health Organization; 2006.
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;(15):539-553.
9. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
10. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. Stat Med. 2005;(24):2911-2935.
11. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;(373):1765-1772.
12. LindgrenCM,Heid IM, Randall JC, et al. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet. 2009;(5):e1000508.
13. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;(42):937-948.
14. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;(34):1826-1833.
15. Kathiresan S, Melander O, Guiducci C, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; (40):189-197.
16. Varbo A, Benn M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG. TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2011;(31):451-457.
17. Heid IM, Boes E, Muller M, et al. Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. Circ Cardiovasc Genet. 2008;(1):10-20.
18. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet. 2009;(41):677-687.
19. Chambers JC, Elliott P, Zabaneh D, et al.Commongenetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet. 2008;(40):716-718.
20. Dupuis J, Langenberg C, Prokopenko I, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;(42):105-116.
21. Prokopenko I, Langenberg C, Florez JC, et al. Variants inMTNR1B influence fasting glucose levels. Nat Genet. 2009;(41):77-81.
22. Sabatti C, Service SK, Hartikainen AL, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2009;(41):35-46.
23. De Silva NM, Freathy RM, Palmer TM, et al. Mendelian randomization studies do not support a role for raised circulating triglyceride levels influencing type 2 diabetes, glucose levels, or insulin resistance. Diabetes. 2011;(60):1008-1018.
24. Islam M, Jafar TH, Wood AR, et al. Multiple genetic variants explain measurable variance in type 2 diabetes-related traits in Pakistanis. Diabetologia. 2012;(55):2193-2204.
25. Klimentidis YC, Chougule A, Arora A, Frazier-Wood AC, Hsu CH. Triglyceride-increasing alleles associated with protection against type-2 diabetes. PLoS Genet. 2015;(11):e1005204.
26. Haase CL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. HDL cholesterol and risk of type 2 diabetes: a Mendelian randomization study. Diabetes. 2015;(64):3328-3333.
27. Holmes MV, Lange LA, Palmer T, et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;(94):198-208.
28. Afzal S, Brondum-Jacobsen P, Bojesen SE, Nordestgaard BG. Vitamin D concentration, obesity, and risk of diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. 2014;(2):298-306.
29. Nordestgaard AT, Thomsen M, Nordestgaard BG. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a Mendelian randomization study. Int J Epidemiol. 2015;(44):551-565.
30. Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies. JAmColl Cardiol. 2015;(66):1552-1562.
31. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;(322): 716-720.
32. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;(17):319-326.
33. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;(116):39-48.
34. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-and NF-κB. Nat Med. 2005;(11):183-190.
35. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;(112):1821-1830.
36. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;(21):1443-1455.
37. Kodama S, Horikawa C, Fujihara K, et al. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis. Am J Epidemiol. 2012;(176):959-969.
38. Kraja AT, Vaidya D, Pankow JS, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes. 2011;(60):1329-1339.
39. Kristiansson K, Perola M, Tikkanen E, et al. Genome-wide screen for metabolic syndrome susceptibility loci reveals strong lipid gene contribution but no evidence forcommongenetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet. 2012;(5): 242-249.
40. Bouma M, Dekker JH, de Sonnaville JJ, et al. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulinusing patients with type 2 diabetes? Diabetes Care. 1999;(22):904-907.
41. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract. 1999;(46):23-27.
42. Verges B. The impact of prandial glucose regulation in practice. Diabetes Nutr Metab. 2002;(15):28-32.
43. International Diabetes Federation. IDF Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org.